CAJ | 학술논문

目的：评价参一胶囊联合卡培他滨维持治疗晚期大肠癌的疗效和安全性。方法对61例经过一线治疗后达到完全缓解、部分缓解或稳定的晚期大肠癌患者，采用随机分组的方法进行维持治疗。其中试验组（30例）应用参一胶囊联合卡培他滨维持治疗，对照组（31例）单用卡培他滨维持治疗。结果试验组和对照组的中位无进展生存期（PFS）分别为10.0个月和8.0个月，试验组无疾病进展生存状况显著优于对照组（P=0.003）。试验组骨髓抑制发生率显著低于对照组（P＜0.05）。结论对于晚期大肠癌患者，参一胶囊联合卡培他滨维持治疗对比单用卡培他滨维持治疗能延长患者的PFS ，减少骨髓抑制的发生。
목적：평개삼일효낭연합잡배타빈유지치료만기대장암적료효화안전성。방법대61례경과일선치료후체도완전완해、부분완해혹은정적만기대장암환자，채용수궤분조적방법진행유지치료。기중시험조（30례）응용삼일효낭연합잡배타빈유지치료，대조조（31례）단용잡배타빈유지치료。결과시험조화대조조적중위무진전생존기（PFS）분별위10.0개월화8.0개월，시험조무질병진전생존상황현저우우대조조（P=0.003）。시험조골수억제발생솔현저저우대조조（P＜0.05）。결론대우만기대장암환자，삼일효낭연합잡배타빈유지치료대비단용잡배타빈유지치료능연장환자적PFS ，감소골수억제적발생。
Objective To observe the clinical effect and safety of Shen Yi capsule plus capecitabine in the mainte-nance treatment of advanced colorectal cancer. Method Sixty-one patients of advanced colorectal cancer after first-line chemotherapy with CRPR and SD were randomized into experiment group administered with Shen Yi capsule and capecitabine (30 cases) or control group receiving capecitabine alone (31 cases). Result The median PFS was 10.0 months in experiment group and 8.0 months in control group, and there was significant difference in between (P=0.003). Bone marrow suppression rate of experiment group was significantly less than that of control group (P <0.05). Conclusion The combination of Shen Yi capsule and capecitabine can prolong PFS of patients, as well as re-duce bone marrow suppression in advanced colorectal cancer when given in maintenance treatment.